MediWound director buys 3,537 shares in open market
MediWound Ltd. director David Morton Fox reported open-market purchases of a total of 3,537 ordinary shares on June 1, 2026, at prices between $13.995 and $14.23 per share.
Rhea-AI Filing Summary
MediWound Ltd. director David Morton Fox reported open-market purchases of a total of 3,537 ordinary shares on June 1, 2026, at prices between $13.995 and $14.23 per share. Other rows in the filing reflect existing holdings only, with no transactions in those securities.
He also holds several equity incentives, including stock options over 6,250 ordinary shares at an exercise price of $17.6000 expiring on March 4, 2036, and Series A warrants over 6,534 ordinary shares at an exercise price of $13.4750 expiring on November 28, 2026. Footnotes state that certain RSUs and options granted on March 4, 2026 vest 100% on the one-year anniversary of that grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 3,537 shares
Net Buy
12 txns
Insider
Fox David Morton
Role
Director
Bought
3,537 shs ($50K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Ordinary Shares | 1,730 | $14.225 | $25K |
| Purchase | Ordinary Shares | 10 | $14.23 | $142.30 |
| Purchase | Ordinary Shares | 1,797 | $13.995 | $25K |
| holding | Series A Warrants | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
Holdings After Transaction:
Ordinary shares — 23,033 shares (Direct);
Series A Warrants — 6,534 contracts (Direct);
Stock Option (right to buy ordinary shares) — 46,541 contracts (Direct)
Footnotes (3)
- F1. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
- F2. There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
- F3. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
Key Figures
Total shares purchased: 3,537 shares
Purchase price (trade 1): $13.995 per share
Purchase price (trade 2): $14.230 per share
+4 more
7 metrics
Total shares purchased
3,537 shares
Open-market purchases on June 1, 2026
Purchase price (trade 1)
$13.995 per share
Ordinary share buy on June 1, 2026
Purchase price (trade 2)
$14.230 per share
Ordinary share buy on June 1, 2026
Purchase price (trade 3)
$14.225 per share
Ordinary share buy on June 1, 2026
Option underlying shares
6,250 shares
Stock option at $17.6000, expiring March 4, 2036
Series A warrant underlying shares
6,534 shares
Series A warrants at $13.4750, expiring November 28, 2026
Net buy direction
3,537 shares net-buy
Transaction summary across reported trades
Key Terms
RSUs, Stock Option (right to buy ordinary shares), Series A Warrants, open-market purchase
4 terms
RSUs financial
"consist of shares underlying RSUs that were granted to the Reporting Person"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
Series A Warrants financial
"Series A Warrants"
Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.
open-market purchase financial
"transaction_action": "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did MediWound (MDWD) report for David Morton Fox?
MediWound director David Morton Fox reported buying 3,537 ordinary shares on June 1, 2026. The purchases were open-market transactions at prices between $13.995 and $14.23 per share, according to the Form 4 disclosure.
Were all securities in David Morton Fox’s MediWound Form 4 actively traded?
No. Only three entries reflect open-market purchases totaling 3,537 ordinary shares. Other rows show existing holdings in RSUs, stock options, and warrants that were included for informational purposes, with no transactions reported in those securities.
What stock options does David Morton Fox hold in MediWound (MDWD)?
David Morton Fox holds several MediWound stock option grants, including options over 6,250 ordinary-share equivalents at a $17.6000 exercise price expiring March 4, 2036, plus additional option grants with varying exercise prices and expirations through 2030–2035.
What MediWound Series A warrants are reported for David Morton Fox?
The Form 4 shows David Morton Fox holding Series A warrants over 6,534 underlying MediWound ordinary shares. These warrants have a $13.4750 exercise price and expire on November 28, 2026, and were listed as holdings rather than new transactions.
How do RSUs factor into David Morton Fox’s MediWound holdings?
Footnotes state that some ordinary shares reported consist of RSUs granted March 4, 2026, which vest 100% on the one-year anniversary of that grant date. These RSU-related holdings were included for informational purposes without new transactions in those securities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
